Chinese Japanese Germany Korea

Sunitinib Malate

Anticancer drug Uses
Sunitinib Malate
Sunitinib Malate structure
Chemical Name:
Sunitinib Malate
CS-308;SU112248;SU 011248;Sunitinib MaL;Malic acid Shu;SU11248; SUTENT;SUNITINIB MALATE;Sunitinib Mablate;SU 11248 (Malate);Sunitanib Maleate
Molecular Formula:
Formula Weight:
MOL File:

Sunitinib Malate Properties

Melting point:
storage temp. 
room temp
DMSO: >10mg/mL
CAS DataBase Reference
341031-54-7(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
SU011248; sunitinib malate
NCI Drug Dictionary
sunitinib malate
  • Risk and Safety Statements
Signal word  Danger
Hazard statements  H360-H372
Precautionary statements  P201-P308+P313
Hazard Codes  T
Risk Statements  61-2-48/25-36/37-22-53
Safety Statements  53-22-36/37-24/25
WGK Germany  2
HS Code  29337900

Sunitinib Malate price More Price(40)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PZ0012 Sunitinib malate ≥98% (HPLC) 341031-54-7 5mg $121 2021-12-16 Buy
Sigma-Aldrich PZ0012 Sunitinib malate ≥98% (HPLC) 341031-54-7 25mg $477 2021-12-16 Buy
Cayman Chemical 13159 Sunitinib Malate ≥98% 341031-54-7 1mg $30 2021-12-16 Buy
Cayman Chemical 13159 Sunitinib Malate ≥98% 341031-54-7 5mg $58 2021-12-16 Buy
Tocris 3768 Sunitinib malate ≥99%(HPLC) 341031-54-7 50 $1001 2021-12-16 Buy

Sunitinib Malate Chemical Properties,Uses,Production

Anticancer drug

Sunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases.
Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy.
The indications of Sunitinib malate are as follows:
1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST).
2, inoperable advanced renal cell carcinoma (RCC).
3, advanced pancreatic endocrine tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.


Anti-cancer drugs


Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3. It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src. Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; IC50s = 250 and 50 nM, respectively). It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC50s = 30 and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day. Formulations containing sunitinib have been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.

Chemical Properties

Yellow Solid


Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.


Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit


A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.

brand name


General Description

Sunitinib is available in 12.5-, 25-, and 50-mg capsules fororal administration for the treatment of advanced RCC andGIST upon the failure of imatinib. The agent is a multikinaseinhibitor and has been shown to inhibit PDGF-R,VEGF-R, Kit, RET, and the colony-stimulating factor receptor(CSR-1R). The result of this spectrum of activity isa slowing of tumor progression and inhibition of angiogenesisboth of which are useful in the highly vascularizedcancers, RCC and GIST. The median TTP (time to tumorprogression) was 27.3 weeks for sunitinib and 6.4 weeks with a median time of 24.1 weeks for sunitinib and 6 weeksfor placebo. The agent is well absorbed upon oral administration,and both the parent and major metabolite are highly(90%–95%) protein bound. Metabolism is mediated primarilyby CYP3A4 to give the N-desethyl derivative, which isthe major metabolite (23%–37%), equally active with theparent and undergoes further metabolism by CYP3A4. Theterminal elimination half-life for the parent and N-desethylderivative are 40 to 60 hours and 80 to 110 hours, respectively.Elimination occurs primarily via the feces. Commonadverse effects of sunitinib include fatigue, diarrhea, yellowskin discoloration, anorexia, nausea, and mucositis.Mild myelosuppression has been reported in patients withGIST including neutropenia, lymphopenia, thrombocytopenia,and anemia. There have been reports of cardiotoxicityincluding decreases in left ventricular ejectionfraction, which occurred in 11% of patients during a GISTstudy.

Biological Activity

Potent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.

Biochem/physiol Actions

Sunitinib has greater bioavailability and potency compared to other inhibitors. It prevents angiogenesis.

Sunitinib Malate Preparation Products And Raw materials

Raw materials

Preparation Products

Sunitinib Malate Suppliers

Global( 303)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497 CHINA 1817 55
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106
+86 (576) 8169-6105 China 886 50
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 China 22607 55
Hangzhou FandaChem Co.,Ltd.
+86-571-56059825 CHINA 9150 55
Guangzhou PI PI Biotech Inc
020-81716319; China 3284 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 26782 60
Anqing Chico Pharmaceutical Co., Ltd.
15380796838 CHINA 341 58
career henan chemical co
+86-0371-55982848 China 29953 58
+86 18953170293
+86 0531-67809011 CHINA 2940 58
0086-13720134139 CHINA 968 58

View Lastest Price from Sunitinib Malate manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2022-01-25 Sunitinib malate
US $16.00 / KG 1KG 99% 20tons Hong Kong Tiansheng New Material Trading Co., Ltd
2022-01-25 Sunitinib malate
US $99.00 / KG 1KG 99% 1 ton Hong Kong Tiansheng New Material Trading Co., Ltd
2021-11-15 Sunitinib Malate
US $160.00 / KG 1KG 99% 500ton/Month Hebei Yirun Sega Biological Technology Co. Ltd

341031-54-7(Sunitinib Malate)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved